ArticleJACC. Asia2026
Burden and Risk Factors of Cardiovascular Diseases in Asia, 1990-2021: An Analysis for GBD 2021.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Article
- Advancing Cardiovascular Disease Prevention in Asian Populations.JACC. Asia · 2026Article
- A Look Towards Next Steps: Trends in Cardiovascular Disease Burden in the Asia Region.JACC. Asia · 2026Article
- Warranty period of a zero coronary artery calcium score in Japanese adults.Japanese journal of radiology · 2026Article
- Bidirectional effect modification between diurnal temperature range and particulate matter on acute myocardial infarction risk.iScience · 2026Article
- Advancing Cardiovascular Risk Stratification in Asian Populations: Opportunities and Remaining Gaps.JACC. Asia · 2026Article
- Pakistan's rising cardiovascular disease burden associated with modifiable risk factors: an urgent appeal for evidence-driven action.Annals of medicine and surgery (2012) · 2026Article
- Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite ongoing prevention efforts, the burden of cardiovascular disease (CVD) continues to rise with rapidly aging population and lifestyle changes. Comprehensive reports on CVD burden for Asia remain limited.
objectivesThe aims of this study were to quantify the CVD burden in Asia from 1990 to 2021 and to investigate associated risk factors and their temporal rank changes.
methodsData from the Global Burden of Disease (GBD) 2021 study were used to estimate the prevalence, disability-adjusted life years (DALYs), and mortality of CVD from 1990 to 2021 across 6 Asian regions, age groups, and sex. Twenty-seven behavioral, environmental, and metabolic risk factors were analyzed.
resultsIn 2021, Asia accounted for 270.4 million DALYs and 11.8 million deaths of CVD, representing 61.3% of global CVD mortality. The age-standardized DALYs rate (ASDR) in Asia exceeded the global average by 8.3%. The ASDR was highest in Central Asia but lowest in the high-income Asia Pacific region among the 6 Asian regions. From 1990 to 2021, ASDR and age-standardized mortality rate declined by 27.5% and 25.4%, respectively, whereas age-standardized prevalence increased by 71.7%. Ischemic heart disease and stroke collectively contributed to more than 80% of CVD deaths. High systolic blood pressure persisted as the leading risk factor, while particulate matter pollution emerged as a leading contributor to CVD burden in Asia.
conclusionsDespite declines in ASDR and age-standardized mortality rate, the absolute CVD burden in Asia has increased sharply. Regional disparities in CVD burden and risk factors profiles highlight the necessity for targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.